Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

511.94 +13.44 (+2.70%)
Delayed Quote Updated: 10:34 AM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
77 78 Next >
News headline image
Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades. ↗
These three should have a lot of room to run. 
Via The Motley Fool
News headline image
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs ↗
Unlock Vertex Pharmaceuticals' pioneering treatments, from the groundbreaking Trikafta for cystic fibrosis to the promising non-opioid painkillers. 
Via Benzinga
News headline image
(VRTX) - Analyzing Vertex Pharmaceuticals's Short Interest ↗
 
Via Benzinga
News headline image
2 Fantastic Growth Stocks to Buy Right Now ↗
Don't overlook these high-growth businesses. 
Via The Motley Fool
News headline image
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
Good news could be just around the corner for two drugmakers not named Novo Nordisk. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy? ↗
Vertex is broadening its portfolio. 
Via The Motley Fool
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $6,000 Today ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals: Buy, Sell, or Hold? ↗
The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run? 
Via The Motley Fool
News headline image
Making Sense of Amazon CEO Andy Jassy's Latest Letter ↗
And that's just part of the interesting news for investors to dig into. 
Via The Motley Fool
News headline image
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today ↗
Could Vertex's growth story continue? 
Via The Motley Fool
News headline image
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now ↗
These stocks could be near major inflection points. 
Via The Motley Fool
News headline image
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever ↗
These stocks probably won't be getting much cheaper. 
Via The Motley Fool
News headline image
3 Relatively Safe Growth Stocks You Can Buy and Hold ↗
Low risk and high-reward potential? These stocks could offer both. 
Via The Motley Fool
News headline image
3 Biotech Stocks Set to Double by 2028 ↗
These are three of the top biotech stocks set to double by 2028. Add them to your portfolio to maximize your potential gains. 
Via InvestorPlace
News headline image
Is Vertex Pharmaceuticals Stock a Millionaire Maker? ↗
Does this pharma stock have the potential to turn a $25,000 investment into seven figures or more? 
Via The Motley Fool
News headline image
Tesla To $123? Here Are 10 Top Analyst Forecasts For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy? ↗
The biotech just added another potential growth driver to its pipeline. 
Via The Motley Fool
News headline image
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock ↗
Vertex just laid claim to an asset that might be very valuable. 
Via The Motley Fool
News headline image
Could This Stock Be the Next Biotech Buyout? ↗
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease. 
Via The Motley Fool
News headline image
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review ↗
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears. 
Via Investor's Business Daily
Topics Economy
News headline image
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact ↗
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth... 
Via Benzinga
News headline image
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday? ↗
Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly lower than expected, albeit with some caveats across different measures... 
Via Benzinga
Topics Economy
News headline image
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024 ↗
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024. 
Via InvestorPlace
News headline image
Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock ↗
Nvidia stock is on the move Thursday after shares of NVDA got an increased price target of $1,100 from Raymond James analysts. 
Via InvestorPlace
News headline image
Apple Spyware Warning: What to Know About ‘Mercenary Spyware Attack’ Alerts ↗
An Apple spyware warning has been sent to iPhone owners in 92 states as they have been targeted by a mercenary spyware attack. 
Via InvestorPlace
News headline image
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today ↗
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
News headline image
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options ↗
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. 
Via Investor's Business Daily
News headline image
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune ↗
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to... 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
77 78 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.